

## **Test Definition: FINA**

NAbFeron (IFNB-1) Neutralizing Antibody Test

#### Overview

#### **Method Name**

Viral Cytopathic Effect Assay

#### **NY State Available**

Yes

## Specimen

## Specimen Type

Serum

#### Specimen Required

**Patient Preparation:** Specimen should be collected either before treatment with interferon or more than 24 hours following the most recent dose. Patient **should not** be on steroid therapy for at least two weeks prior to testing.

Collection Container/Tube: Red top or serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 2 mL serum

**Collection Instructions:** 

- 1. Within 48 hours of collection, centrifuge and aliquot 2 mL of serum into a plastic vial.
- 2. Send refrigerate.

## **Specimen Minimum Volume**

Serum: 0.5 mL

#### **Reject Due To**

All specimens will be evaluated by the processing and performing laboratories for test suitability.

## **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Serum	Refrigerated (preferred)	28 days	
	Ambient	72 hours	
	Frozen	180 days	

## **Clinical & Interpretive**

## **Clinical Information**

Refer to www.athenadiagnostics.com/view-full-catalog



# **Test Definition: FINA**

NAbFeron (IFNB-1) Neutralizing Antibody Test

#### **Reference Values**

<1:20

#### **Cautions**

The present of neutralizing antibodies to interferon beta, especially in persistently high titers, may be associated with reduction in the clinical effectiveness of interferon beta therapy.(1) Although the measurement of Nabs can add to the clinical and imaging information used to assess the efficacy of interferon beta therapy, these results should be interpreted in the context of clinical presentation and medical history.(2,3)

Although rare, false positive or false negative results may occur. All results should be interpreted in the context of clinical findings, relevant history, and other laboratory data.

#### **Clinical Reference**

- 1. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007;68(13):977-984
- 2. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010;9(7):740-750
- 3. Creeke Pl, Farrell RA. Clinical testing for neutralizing antibodies to interferon-ß in multiple sclerosis. Ther Adv Neurol Disord. 2013;6(1):3-17

## **Performance**

#### **PDF Report**

Referral

#### Day(s) Performed

Monday through Friday

#### Report Available

14 to 25 days

## **Performing Laboratory Location**

Athena Diagnostics

#### Fees & Codes

#### Fees

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.



# **Test Definition: FINA**

NAbFeron (IFNB-1) Neutralizing Antibody Test

#### **Test Classification**

This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. .

## **CPT Code Information**

86382

## **LOINC®** Information

Test ID	Test Order Name	Order LOINC® Value
FINA	NAbFeron (IFN-B) Antibody	Not Provided

Result ID	Test Result Name	Result LOINC® Value
Z0083	NAbFeron (IFN-B) Antibody	Not Provided